These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
862 related items for PubMed ID: 14695158
1. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ. Clin Cancer Res; 2003 Dec 15; 9(17):6534-44. PubMed ID: 14695158 [Abstract] [Full Text] [Related]
2. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE. Clin Cancer Res; 2005 Jan 01; 11(1):306-14. PubMed ID: 15671560 [Abstract] [Full Text] [Related]
3. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T. Cancer; 2005 May 01; 103(9):1800-9. PubMed ID: 15786421 [Abstract] [Full Text] [Related]
4. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ. J Natl Cancer Inst; 2003 Mar 19; 95(6):458-70. PubMed ID: 12644539 [Abstract] [Full Text] [Related]
5. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL, Fidler IJ. Cancer Res; 2005 Nov 15; 65(22):10371-80. PubMed ID: 16288027 [Abstract] [Full Text] [Related]
6. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R. J Cell Physiol; 2006 Jul 15; 208(1):220-8. PubMed ID: 16575905 [Abstract] [Full Text] [Related]
7. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M. Clin Cancer Res; 2002 Nov 15; 8(11):3584-91. PubMed ID: 12429650 [Abstract] [Full Text] [Related]
8. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M. J Invest Dermatol; 2004 Feb 15; 122(2):400-5. PubMed ID: 15009722 [Abstract] [Full Text] [Related]
9. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit). Moawad EY. J Gastrointest Cancer; 2015 Sep 15; 46(3):272-83. PubMed ID: 25985771 [Abstract] [Full Text] [Related]
10. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Apte SM, Fan D, Killion JJ, Fidler IJ. Clin Cancer Res; 2004 Feb 01; 10(3):897-908. PubMed ID: 14871965 [Abstract] [Full Text] [Related]
12. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM. J Clin Invest; 2007 Aug 01; 117(8):2114-22. PubMed ID: 17641778 [Abstract] [Full Text] [Related]
13. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Sumida T, Kitadai Y, Shinagawa K, Tanaka M, Kodama M, Ohnishi M, Ohara E, Tanaka S, Yasui W, Chayama K. Int J Cancer; 2011 May 01; 128(9):2050-62. PubMed ID: 21387285 [Abstract] [Full Text] [Related]
16. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R. Cancer; 2008 May 15; 112(10):2119-29. PubMed ID: 18338812 [Abstract] [Full Text] [Related]
17. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Int J Cancer; 2007 Dec 15; 121(12):2606-14. PubMed ID: 17691110 [Abstract] [Full Text] [Related]